

Community Cancer Care

Commission On Cancer

Standard 4.6: Monitoring Compliance with Evidence-Based Guidelines

Each year, a physician member of the cancer committee performs a study to assess whether patients within the program are evaluated and treated according to evidence-based national treatment guidelines. Study results are presented to the cancer committee and documented in cancer committee minutes.



From day one.

Compliance 2019

Primary aim: Review the rate of pre-treatment brain MRI in patients with stage II - IV non-small cell lung cancer.

Criteria: Patients diagnosed and treated from January 1, 2017 through December 31, 2018 at Community Medical Center

Evidence-Based National Guidelines: National Cancer Comprehensive Network, *Non-Small Cell Lung Cancer*, version 1. 2019


Date of Study: October 2019

Physician Member: Dr. Michelle Proper



Brain MRI

- NCCN recommends the following:



Non-Small Cell Lung Cancer

- Retrospective chart review

Results

- 40 patients
 - 18 patients included in this study
 - 22 patients excluded:
 - 3 patients not NSCLC diagnosis (2 small cell, 1 mesothelioma)
 - 6 patients were stage I
 - 2 patients had pacemaker
 - 5 patients went immediately to hospice or died
 - 6 patients treated at St. Pat's

Review the rate of pre-treatment MRI brain imaging in stage II- IV non-small cell lung cancer patients.

PRIMARY AIM

Brain MRI

- 17 out of 18 patients had a brain MRI prior to starting treatment.
 - 1 patient was initially thought to be node negative (does not require Brain MRI) but found to have involved LNs at time of surgery. Patient was treated with adjuvant chemotherapy without pretreatment MRI.

Recommendations

- Primary Aim: Pre-treatment Brain MRI on all stage II – IV non-small cell lung cancer patients prior to treatment
 - Overall excellent rate (94%) of pre-treatment brain MRI
 - The 1 patient without brain MRI was treated by a physician that has since retired